TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11374113

Group type: EXPERIMENTAL
Intervention: Low dosage monophasic oral contraceptives (OC) - days 5-8
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low dosage monophasic oral contraceptives (OC) - days 19-21
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low dosage monophasic oral contraceptives (OC) - run 5 days 5-8
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low dosage monophasic oral contraceptives (OC) - run 5 days 19-21
Number of subjects: 9
Study: 9589244

Group type: EXPERIMENTAL
Intervention: high‐mixture 75/25 insulin lispro/NPL insulin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: mid‐mixture 50/50 insulin lispro/NPL insulin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: low‐mixture 25/75 insulin lispro/NPL insulin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: insulin lispro
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NPL insulin
Number of subjects: 30
Study: 15278585

Group type: EXPERIMENTAL
Intervention: Atropinized group (0.015 mg.kg(‐1) i.m.)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non‐atropinized group (A(‐))
Number of subjects: 43
Study: 3924984

Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium (CS) 20 mg inhaled four times daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Long-acting Theophylline (LAT) administered twice daily to achieve mean blood levels of 14.0 +/- 1.6 SEM micrograms per milliliters
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium (CS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Long-acting Theophylline (LAT)
Number of subjects: 13
Study: 30272170

Group type: EXPERIMENTAL
Intervention: Dulaglutide (Trulicity®) 1.5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20
Study: 29160002

Group type: EXPERIMENTAL
Intervention: J‐Tip with 1% lidocaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Topical anesthetic (TA) cream
Number of subjects: 58
Study: 26775671

Group type: EXPERIMENTAL
Intervention: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT), 4 sessions at 2‐week intervals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clobetasol propionate (0.05%), daily for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clobetasol propionate (0.05%)
Number of subjects: 40
Study: 25252230

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: MD
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: AD
Number of subjects: 212
Study: 23248832

Group type: COMPARATOR
Intervention: CD-ROM
Number of subjects: 29

Group type: COMPARATOR
Intervention: Simulation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination
Number of subjects: 29
Study: 19763992

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 21
Study: 17894707

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical excision (SE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary BCC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recurrent BCC
Number of subjects: 0
Study: 15048062

Group type: EXPERIMENTAL
Intervention: Rescue therapy combining amsacrine 120 mg/m(2)/day (days 1-3), cytarabine 1 g/m(2)/12 h (days 1-5), and etoposide 100 mg/m(2)/day (days 1-5)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rescue therapy combining amsacrine, cytarabine, and etoposide
Number of subjects: 40
Study: 12516985

Group type: EXPERIMENTAL
Intervention: Bayesian statistical methods for design and analysis of cost-effectiveness trials
Number of subjects: 0
Study: 9421649

Group type: EXPERIMENTAL
Intervention: 1.5 pitch helical CT
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.0 pitch helical CT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 30
Study: 8556567

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) containing BKC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BKC plus placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 22
Study: 2169077

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (subcutaneous injection once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection once daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 40
Study: 40584

Group type: EXPERIMENTAL
Intervention: Oral cimetidine (1 g daily for 1 week)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: H1 receptor antagonist chlorpheniramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31587493

Group type: EXPERIMENTAL
Intervention: PDT with active formulation cream (licochalcone A, L-carnitine, and decanediol)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PDT with active formulation cream
Number of subjects: 29

Group type: COMPARATOR
Intervention: PDT with vehicle cream
Number of subjects: 29
Study: 30971229

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 28808723

Group type: EXPERIMENTAL
Intervention: High glycemic load diet
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low glycemic load diet
Number of subjects: 80
Study: 26049662

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 322

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 322
Study: 23810356

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise
Number of subjects: 66

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 66
Study: 21696114

Group type: EXPERIMENTAL
Intervention: Gold brackets
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stainless steel brackets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plastic brackets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ceramic brackets
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral hygiene indices (VPI and GBI)
Number of subjects: 40
Study: 19432036

Group type: EXPERIMENTAL
Intervention: Intermittent balneotherapy in a sulfur pool heated to 35-36 degrees C, twice weekly for 6 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group treated in a Jacuzzi filled with tap water heated to 35-36 degrees C
Number of subjects: 44
Study: 16442957

Group type: EXPERIMENTAL
Intervention: Didactic lecture followed by instructional SP interaction (Group A)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Instructional SP interaction followed by didactic lecture (Group B)
Number of subjects: 143
Study: 15564181

Group type: EXPERIMENTAL
Intervention: Sentinel node lymphadenectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 100
Study: 11401935

Group type: EXPERIMENTAL
Intervention: Deferoxamine (500 mg intra-arterially over 1 hour)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal volunteers)
Number of subjects: 0
Study: 9207772

Group type: EXPERIMENTAL
Intervention: Glass-ionomer restorations
Number of subjects: 666

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 666

Group type: COMPARATOR
Intervention: Surfaces adjacent to amalgam restorations
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Surfaces adjacent to glass-ionomer restorations
Number of subjects: 666
Study: 8010314

Group type: EXPERIMENTAL
Intervention: Oral ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of dexamethasone and metoclopramide
Number of subjects: 0
Study: 3191941

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30117361

Group type: EXPERIMENTAL
Intervention: Brief education group (one‐page double‐sided document)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Longer education group (10‐page document)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care (standard ED discharge instructions)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Trauma control group (non‐concussion)
Number of subjects: 255
Study: 27836586

Group type: EXPERIMENTAL
Intervention: IUD insertion (either levonorgestrel-releasing intrauterine system or copper-IUD) offered at follow-up visit 1-4 weeks after MTOP.
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Treatment for presumed adverse events (administration of antibiotics, misoprostol or surgical evacuation).
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: IUD expulsion rate in the intervention group.
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control group follow-up and contraceptive provision.
Number of subjects: 606

Group type: COMPARATOR
Intervention: Treatment for presumed adverse events in the control group.
Number of subjects: 606

Group type: COMPARATOR
Intervention: Timing of adverse events in the control group.
Number of subjects: 606
Study: 25084740

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional restorative technique (CT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both ART and CT
Number of subjects: 99
Study: 23313352

Group type: EXPERIMENTAL
Intervention: 15° tilt-in-space and 120° recline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 25° tilt-in-space and 120° recline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 35° tilt-in-space and 120° recline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 35° tilt-in-space and 100° recline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 15° tilt-in-space and 100° recline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 25° tilt-in-space and 100° recline
Number of subjects: 11
Study: 21456091

Group type: EXPERIMENTAL
Intervention: Fibrin sealant applied before wound closure
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard wound closure (Control)
Number of subjects: 74
Study: 19318293

Group type: EXPERIMENTAL
Intervention: Haloperidol plus ondansetron (H+O)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Haloperidol (H)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Ondansetron (O)
Number of subjects: 210
Study: 16676340

Group type: EXPERIMENTAL
Intervention: Psychoeducation and stress management training to caregivers
Number of subjects: 22

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 22
Study: 15257785

Group type: EXPERIMENTAL
Intervention: Self-evaluation with the expectation to improve
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-evaluation without the expectation to improve
Number of subjects: 0
Study: 11403977

Group type: EXPERIMENTAL
Intervention: Buserelin (low dose gonadotropin releasing hormone agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated PMDD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buserelin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 9423389

Group type: EXPERIMENTAL
Intervention: Transparent dressing and StatLock i.v./PICC
Number of subjects: 105

Group type: COMPARATOR
Intervention: Transparent dressing and tape (control group)
Number of subjects: 105
Study: 8214647

Group type: EXPERIMENTAL
Intervention: Epinephrine (30 ng.kg‐1.min‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amrinone (1.5 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of amrinone and epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2871915

Group type: EXPERIMENTAL
Intervention: System of care with medical assistant overseeing screening and education (experimental group)
Number of subjects: 32124

Group type: COMPARATOR
Intervention: Usual practices (control group)
Number of subjects: 32124
Study: 28669606

Group type: EXPERIMENTAL
Intervention: 150 minutes per week of aerobic exercise (low-dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 300 minutes per week of aerobic exercise (high-dose)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 39
Study: 27391774

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise programme (30 min continuous cycling thrice weekly during dialysis)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise programme
Number of subjects: 130
Study: 24215215

Group type: EXPERIMENTAL
Intervention: Oral administration of azithromycin (AZM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of cefazolin (CEZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both AZM and CEZ
Number of subjects: 0
Study: 22334806

Group type: EXPERIMENTAL
Intervention: Unattended polysomnography at baseline and auto-titrating CPAP therapy for up to one year
Number of subjects: 318

Group type: COMPARATOR
Intervention: Usual care and unattended polysomnography at the end of the study
Number of subjects: 318
Study: 21521204

Group type: EXPERIMENTAL
Intervention: Sumatriptan-naproxen sodium (85 mg sumatriptan and 500 mg naproxen sodium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sumatriptan-naproxen sodium
Number of subjects: 0
Study: 18357500

Group type: EXPERIMENTAL
Intervention: Stanger bath therapy and exercise program (n = 30)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional exercise program alone (n = 28)
Number of subjects: 58
Study: 16522454

Group type: EXPERIMENTAL
Intervention: FSC 100/50 microg twice daily
Number of subjects: 641

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 microg twice daily
Number of subjects: 641
Study: 12694138

Group type: EXPERIMENTAL
Intervention: Sedation with propofol
Number of subjects: 18

Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 18
Study: 11075843

Group type: EXPERIMENTAL
Intervention: Rizatriptan wafer 10 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 8792758

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with high dosage and bilateral electrode placement
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with low dosage and right unilateral electrode placement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 1641599

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 22
Study: 6689302

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study: 31079057

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 941
Study: 31590426

Group type: EXPERIMENTAL
Intervention: Cyano-B12 (CN-B12) capsules (2 × 2.8 µg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Whey powder with endogenous hydroxo-B12 (HO-B12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cyano-B12 (CN-B12) capsules
Number of subjects: 35
Study: 29911775

Group type: EXPERIMENTAL
Intervention: Silver nanoparticle gel with 2.5% benzoyl peroxide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Clindamycin gel with 2.5% benzoyl peroxide
Number of subjects: 64
Study: 25761508

Group type: EXPERIMENTAL
Intervention: Pupillometry variables (LED light stimulus test)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Cardiac autonomic neuropathy diagnosis
Number of subjects: 384
Study: 24321620

Group type: EXPERIMENTAL
Intervention: High-risk very preterm infants
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal term infants
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low-risk very preterm infants
Number of subjects: 82
Study: 23041227

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finger-stick blood glucose (FSBG)
Number of subjects: 0
Study: 19402373

Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSAs)
Number of subjects: 0
Study: 17580443

Group type: EXPERIMENTAL
Intervention: Acupuncture (Xingnao Kaiqiao Zhenfa)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Medication (Amitriptyline 50 mg/d initially, increased to 200 mg/d)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 256

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 256
Study: 15064253

Group type: EXPERIMENTAL
Intervention: Computerized test battery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional test battery
Number of subjects: 50
Study: 11523414

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 9934405

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 mcg) inhaled before the methacholine test
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 16
Study: 7921716

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31965573

Group type: EXPERIMENTAL
Intervention: Hypovolaemic phlebotomy (7-10 ml per kg whole blood removed, without intravenous fluid replacement)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hypovolaemic phlebotomy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hypovolaemic phlebotomy (high-risk patients)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard care (high-risk patients)
Number of subjects: 62
Study: 31302049

Group type: EXPERIMENTAL
Intervention: Moderate to severe malnutrition risk (GNRI <92)
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Low malnutrition risk (GNRI 92 to <98)
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Absence of malnutrition risk (GNRI ≥98)
Number of subjects: 1677
Study: 28060581

Group type: EXPERIMENTAL
Intervention: Treatment group (n = 20)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 404
Study: 25943048

Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Descemet stripping automated endothelial keratoplasty (DSAEK)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patient preference for better performing eye
Number of subjects: 15
Study: 24643490

Group type: EXPERIMENTAL
Intervention: Intervention B (60 hours of physical activities)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intervention A (40 hours of physical activities)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intervention B
Number of subjects: 62
Study: 21451952

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 679
Study: 18061648

Group type: EXPERIMENTAL
Intervention: CALMA intervention (culturally adapted family asthma management intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CALMA intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17216727

Group type: EXPERIMENTAL
Intervention: Saccharine (22.5 mg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Combination of saccharine (22.5 mg) and cyclamate (150 mg)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 14584388

Group type: EXPERIMENTAL
Intervention: Pranlukast therapy for 4 weeks, continued for Group I for an additional two years.
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pranlukast therapy continued for Group II for one more year after showing a 5% or greater increase in PEFR after one year.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Medication was suspended for Group III after failing to show improvement in PEFR after one year.
Number of subjects: 81
Study: 11068313

Group type: EXPERIMENTAL
Intervention: Stage T1c cancer
Number of subjects: 720

Group type: COMPARATOR
Intervention: Stage T2 cancer diagnosed in the pre-PSA era
Number of subjects: 720

Group type: COMPARATOR
Intervention: Men without cancer
Number of subjects: 720
Study: 8879928

Group type: EXPERIMENTAL
Intervention: 0.2% isoeugenol in ethanol (ROAT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Patch testing with serial dilutions of isoeugenol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Use testing on the neck for 14 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Patch testing with isoeugenol
Number of subjects: 19
Study: 1552037

Group type: EXPERIMENTAL
Intervention: General Inquiry method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Specific Inquiry method
Number of subjects: 0
Study: 3894338

Group type: EXPERIMENTAL
Intervention: Molindone hydrochloride
Number of subjects: 31

Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 31
Study: 31404547

Group type: EXPERIMENTAL
Intervention: Tweeting via TSSMN
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (non‐tweeted) group
Number of subjects: 112
Study: 30654471

Group type: EXPERIMENTAL
Intervention: Standard in Lab (SL) protocol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Abbreviated in Lab (AL) protocol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Abbreviated with Freedom (AF) protocol
Number of subjects: 18
Study: 27853876

Group type: EXPERIMENTAL
Intervention: Intermittent non-invasive ventilation (NIV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no NIV)
Number of subjects: 16
Study: 26427960

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Exercise (WBVE) + Quadriceps Resistance Exercise (QRE)
Number of subjects: 99
Study: 24370760

Group type: EXPERIMENTAL
Intervention: Talk Test (TT)
Number of subjects: 64
Study: 23091101

Group type: EXPERIMENTAL
Intervention: Rituximab every 2 months for 1 year
Number of subjects: 477

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 477